These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19532079)

  • 1. HIV entry: new insights and implications for patient management.
    Hughes A; Nelson M
    Curr Opin Infect Dis; 2009 Feb; 22(1):35-42. PubMed ID: 19532079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV type 1 tropism and inhibitors of viral entry: clinical implications.
    Weber J; Piontkivska H; Quiñones-Mateu ME
    AIDS Rev; 2006; 8(2):60-77. PubMed ID: 16848274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    McKinnell JA; Saag MS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HIV attachment and entry for therapy.
    Strizki J
    Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410
    [No Abstract]   [Full Text] [Related]  

  • 12. The epidemiology of HIV coreceptor tropism.
    Hoffmann C
    Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Integrase inhibitor, CCR5 antagonist, fusion inhibitor].
    Gatanaga H
    Nihon Rinsho; 2010 Mar; 68(3):520-4. PubMed ID: 20229801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 entry inhibitors: an overview.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Maraviroc: clinical trials results].
    Chidiac C; Katlama C; Yeni P
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S17-23. PubMed ID: 18455058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
    Singh IP; Chauthe SK
    Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.
    Kümmerle T; Lehmann C; Hartmann P; Wyen C; Fätkenheuer G
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1773-85. PubMed ID: 19888873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current tests to evaluate HIV-1 coreceptor tropism.
    Rose JD; Rhea AM; Weber J; Quiñones-Mateu ME
    Curr Opin HIV AIDS; 2009 Mar; 4(2):136-42. PubMed ID: 19339953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.